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Abstract Piericidin is a potent inhibitor of the mitochondrial
and bacterial type I NADH-ubiquinone oxidoreductases (Com-
plex I) and is considered to bind at or close to the ubiquinone
binding site(s) of the enzyme. Piericidin-resistant mutants of the
bacterium Rhodobacter capsulatus have been isolated and the
present work demonstrates that a single missense mutation at the
level of the gene encoding the peripheral 49-kDa/NUOD subunit
of Complex I is definitely associated with this resistance. Based
on this original observation, we propose a model locating the
binding site for piericidin (and quinone) at the interface between
the hydrophilic and hydrophobic domains of Complex I.
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1. Introduction
The NADH-ubiquinone oxidoreductase (Complex I, EC
1.6.5.3) catalyzes the ¢rst step of oxidative phosphorylation,
i.e. the oxidation of NADH by ubiquinone. Complex I cou-
ples this oxidoreduction reaction with an active proton trans-
port across the mitochondrial inner membrane or the bacterial
cytoplasmic membrane. In the case of bovine Complex I, this
oligomeric enzyme is composed of up to 43 di¡erent subunits
[1] assembled in two major domains. The peripheral domain is
nuclearly encoded and bears the catalytic NADH binding site.
The membranous domain is mainly constituted of the 7 so-
called ND subunits (ND1, ND2, ND3, ND4, ND4L, ND5
and ND6) encoded by the mitochondrial genome or the equiv-
alent NUOH-NUON plus NUOB subunits in the bacteria.
The most recent enzymatic models attribute a key role to
bound ubiquinones distinct from the substrate quinone in
proton transport processes carried out by Complex I [2^4].
Many inhibitors targeting the Complex I are considered to
bind at, or close to, the quinone binding sites (for review
see [5]). Photoreactive analogues of the classical Complex I
inhibitor rotenone were found to label ND1 [6,7] but the
de¢nite location of the quinone binding site remains to be
ascertained. Genetic studies of inhibitor-resistant mutants
have proved an e⁄cient and reliable way to map the quinone
binding sites of other quinone-dependent enzymes, such as the
photosynthetic reaction center and the cytochrome bc1 com-
plex of photosynthetic purple bacteria [8,9], as has been con-
¢rmed by recent crystallographic studies [10,11]. In the spe-
ci¢c case of Complex I, pathogenic mutations of the human
ND1 or ND4 genes have been reported to slightly alter both
the interaction of Complex I with quinones and its sensitivity
to rotenone [12,13]. This pointed to the subunits ND1 and
ND4 as potential candidates for the binding of quinone and
rotenone. In the eukaryotic system, these subunits are mito-
chondrially encoded, which severely limits the possibility for
genetic studies of inhibitor and quinone binding sites. Human
and Drosophila cell lines resistant to rotenone have been iso-
lated in vitro [14,15] but their resistance did not appear to be
related to Complex I. On the other hand, taking advantage of
the e⁄ciency of bacterial genetics, we isolated Rhodobacter
capsulatus mutants which synthesize a piericidin- and rote-
none-resistant Complex I [16]. In the present report, we dem-
onstrate that this resistance results from a mutation in the
bacterial NUOD subunit equivalent to the hydrophilic 49-
kDa subunit of mitochondrial Complex I. This unexpected
result appears to contradict the data presented above that
suggested a localization of the rotenone and piericidin binding
sites at the level of the ND subunits. However, this apparent
discrepancy can be rationalized in a model locating the pier-
icidin binding site at the interface between the peripheral and
membranous domains of Complex I.
2. Materials and methods
The mutants of R. capsulatus resistant to piericidin are named
PiRA, PiRB, PiRC and PiRD [16] and were derived from strain W1
[17]. This strain was obtained from the wild-type strain B10 by silent
insertion of the KIXX kanamycin resistance cartridge in the intergenic
region between nuoI and nuoJ [17]. In the present work, the nuoA-D
region from strain B10 was cloned and sequenced using manual tech-
niques previously described [18]. The nuo operon of the PiRC mutant
strain was sequenced after ampli¢cation by PCR, using the automated
sequencing facility of Genome Express SA (France). Automated re-
sequencing of the previously characterized nuoH-nuoN region of wild-
type R. capsulatus (B10) nuo operon revealed a single discrepancy with
the manually determined sequence [18] (an additional G should be
added to a track of 3 Gs within the nuoL gene). This correction has
been entered in the sequence of the entire R. capsulatus nuo operon we
deposited in GenBank (GenBank accession no. AF029365).
To check for the causality of the mutation NUODV407M with
respect to piericidin-resistant phenotype, the mutated nuoD gene
from PiRC mutant was reintroduced into an independent wild-type
background by homologous recombination. For this, a BamHI-XhoI
fragment (5868 bp long) containing the wild-type R. capsulatus nuoA-
E genes (Fig. 1) was cloned into suicide plasmid pPHU281 [19]. The
resulting construction (pJP7DB) presents two BglII restriction sites
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delimiting a 1013-bp restriction fragment that contains the 3P part of
the nuoD gene and the 5P part of nuoE (Fig. 1). The wild-type 1013-bp
BglII fragment was replaced by the equivalent fragment ampli¢ed by
PCR from PiRC genomic DNA giving plasmid pED16. The plasmid
pED16, or the control plasmid pJP7DB, were transferred into B10 by
biparental conjugation as previously described [17]. After conjugation-
al transfer, the cells were spread onto a selective medium to screen for
piericidin-resistant clones. As direct selection on piericidin containing
medium is not stringent enough to select for piericidin-resistant mu-
tants, we used a two-step screening strategy [16]. Conjugated cells
were ¢rst spread on a solid medium containing 2.5 WM piericidin-A
and 10 WM myxothiazol and incubated under aerobic conditions.
These conditions allow the growth of R. capsulatus colonies resistant
either to piericidin or to myxothiazol. Myxothiazol totally inhibits
photosynthetic growth of R. capsulatus by blockade of cyclic photo-
synthesis at the level of the bc1 complex, so we could then easily
discriminate myxothiazol-resistant mutants from piericidin-resistant
mutants [16].
All other biochemical and microbiological procedures used in the
present publication were as previously described [16,17].
3. Results
We previously isolated piericidin-resistant mutants (PiR) of
R. capsulatus displaying a decrease in piericidin sensitivity of
at least 30 times in comparison to strains W1 or B10 [16]. The
maximal NADH oxidase activities of the mutants were
slightly decreased (about 30%) whereas their deamino-
NADH-ferricyanide oxidoreductase activities were identical
to those of the wild-type enzyme [16]. This suggested that
piericidin resistance was associated with a rather limited alter-
ation in the quinone binding region of the bacterial Complex
I. Piericidin-resistant mutants also appeared to be resistant to
rotenone. In the literature, the mitochondrial subunits ND1
and ND4 are considered as the best candidates for the loca-
tion of the quinone and rotenone binding sites. However, no
mutation was identi¢ed either in nuoH and nuoM equivalent
genes, or in the remaining 3P region of the nuo operon from
the mutants PiRA, PiRB and PiRC. This prompted us to ana-
lyze the 5P region of R. capsulatus nuo operon.
This region of the R. capsulatus nuo operon (nuoA-nuoG)
has only been partially characterized so far [20,21]. To locate
the genetic alteration associated with piericidin resistance, we
undertook the complete sequencing of the 5P regions of the
PiRC and wild-type nuo operons, corresponding to nuoA-G
genes (Fig. 1) (10 376 bp). Except for an extension of the
nuoE gene and some divergences in the supernumerary open
reading frames previously noted [20,21], this 5P region of the
nuo operon is highly homologous to the P. denitri¢cans nqo
operon [22]. In contrast to E. coli, in which nuoC and nuoD
are fused [23], the R. capsulatus and P. denitri¢cans nuoC and
nuoD genes encode two separate proteins, which are related to
subunits 30 kDa and 49 kDa of mitochondrial Complex I.
The comparative sequencing of the wild-type (B10) and
PiRC nuo operons allowed the identi¢cation of a unique
GCA transition at position 1219 of the nuoD gene of PiRC
(Fig. 1). This missense mutation changes the valine residue at
position 407 of R. capsulatus NUOD subunit into a methio-
nine (mutation NUODV407M).
The NUODV407M mutation introduces an additional
NlaIII restriction site within the nuoD gene. This allowed us
to design a direct restriction site-PCR test for the presence of
the mutation. A 111 bp long fragment encompassing position
1219 of the nuoD gene was generated by PCR using primers
IJPR2 and IJPR9. When digested with NlaIII PCR products
presenting the NUODV407M mutation are cleaved into two
fragments 87 bp and 24 bp long, respectively, whereas the
wild-type PCR product remains uncleaved. Restriction analy-
sis of the PCR products thus demonstrated the presence of the
mutation in mutants PiRA, PiRB and PiRD and its absence in
B10, W1, and myxothiazol resistant mutants (MyxR) isolated
in the same experiment as the PiR mutants (Fig. 2).
To con¢rm the e¡ect of the identi¢ed NUODV407M muta-
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Fig. 1. Structure of the nuoA-nuoG part of the R. capsulatus operon and localization of the NUODV407M mutation. Top: Map of the 5P re-
gion of R. capsulatus nuo operon. This region (from the MaeI restriction site to the previously identi¢ed BamHI site) has now been completely
sequenced (this work, GenBank accession no. AF029365). The nuoH-nuoN region of the R. capsulatus nuo operon [18] is not represented and
starts at the BamHI site indicated at the right of the present map. The mutation NUODV407M is located at the extreme 3P end of nuoD gene
(position indicated by a star). The BamHI (left site) and XhoI restriction sites delimiting the insert of plasmid pJP7DB are indicated, as well as
the two BglII restriction sites present in this insert. Bottom: Alignments of the peptidic sequences of the carboxy-terminus of NUOD/49-kDa
subunits from di¡erent origins: R. capsulatus NUOD (this work); P. denitri¢cans NQO4 (accession number: P29916); bovine 49 kDa (accession
number: P17694); N. crassa 49 kDa (accession number: P22142); wheat mitochondrial 49 kDa (accession number: S53862); Thermus thermo-
philus NQO4 (accession number: Q56220); E. coli NUOCD (accession number: AE000317). Shaded blocks correspond to residues conserved in
at least 5 out of the 7 aligned sequences. Val407CMet mutation observed in PiR mutants is indicated by an arrow.
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tion, this mutation was reintroduced into an independent ge-
netic background, i.e. the parental B10 strain. For this pur-
pose, we ¢rst constructed a suicide plasmid (pJP7DB) contain-
ing the 5P region of the B10 nuo operon from nuoA to nuoE
(see Section 2). In a second step, this construction was modi-
¢ed by replacement of the 1013-bp BglII restriction fragment
encompassing the 3P end of nuoD (see Fig. 1) by the mutated
BglII fragment issued from the PiRC genome. This construc-
tion was called pED16. Following conjugational transfers of
pJP7DB and pED16 plasmids into B10 strain, the R. capsu-
latus conjugates were plated on solid medium containing both
myxothiazol and piericidin under aerobic dark growth condi-
tions as previously described [16]. This screening allows for
the isolation of mutants resistant to either myxothiazol or
piericidin. Applying this screening procedure to bacteria is-
sued from the conjugation with the pJP7DB construction
led to the appearance of few clones, and all these clones
proved myxothiazol resistant. On the contrary, more than
80% of the clones issued from pED16 conjugation proved
piericidin resistant as illustrated in Fig. 2 for six randomly
picked clones (clones 1A1 to 1A6). Among these clones only
clone 1A1 remained sensitive to piericidin and displayed
myxothiazol resistance. Using the restriction site-PCR test
described above, we demonstrated that all the clones except
clone 1A1 had actually integrated the NUODV407M muta-
tion (Fig. 2). Restriction site-PCR further demonstrated that
piericidin resistance was associated with a true gene replace-
ment as only the mutated copy of nuoD gene (i.e. the copy
presenting the NlaIII site) was observed in piericidin-resistant
mutants (Fig. 2). Thus, we observed a perfect correlation be-
tween the appearance of piericidin resistance and the transfer
of NUODV407M mutation.
4. Discussion
The NUOD/49-kDa subunit is associated with the periph-
eral domain of Complex I [24]. An electron microscopy study
of N. crassa Complex I using an Fab fragment directed
against the 49-kDa subunit for immunodecoration indicated
that this protein is located in the vicinity of the membrane
domain [25]. Quinones and inhibitors are usually considered
to bind to two binding sites located within the membrane
domain of Complex I [5^7,12,13]. However, quinones are am-
phiphatic molecules presenting a polar cyclic head and a hy-
drophobic isoprenyl tail. Identi¢cation of a mutation in the
nuoD gene associated with piericidin resistance demonstrates
the necessity for a critical reappraisal of the location of Com-
plex I quinone and inhibitor binding sites in the light of the
structural data available for other quinone dependent en-
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Fig. 3. Model for the organization of the piericidin/rotenone binding
site at the interface between membranous and peripheral domains
of Complex I. This model represents the possible contribution of
NUOD (49 kDa) and NUOH (ND1) subunits in the organization
of the piericidin binding site. The NUOD subunit has been repre-
sented on the internal side of the L-shaped Complex I to comply
with the localization from electron-microscopic studies [5]. Bound
piericidin or ubiquinone is schematized as a black molecule.
Fig. 2. Reconstruction of NUODV407M mutation in the parental
B10 strain. Mutation NUODV407M was reintroduced into the B10
background by homologous recombination. Genotypes and pheno-
types of recombinant clones 1A1^1A6 were analyzed in comparison
to the di¡erent reference and parental strains (B10, W1, Myx1,
PiRC) used in this study. From bottom to top: line 1: Names of
the di¡erent strains. Line 2: Myxothiazol resistance phenotype; the
letters R/S stand for myxothiazol resistant/sensitive phenotype when
grown under anaerobic photosynthetic conditions in the presence of
this inhibitor. Lower panel: Restriction site-PCR characterization of
nuoD gene. A 111-bp long fragment encompassing NUODV407M
mutation was generated by PCR using primers IJPR2 (AT-
CATCGGCACGATG) and IJPR9 (CCCAGGCGCGGTTGGC).
When digested with the restriction enzyme NlaIII, PCR products
presenting the NUODV407M mutation are cleaved into 2 fragments
of 87 bp and 24 bp (the 24-bp fragment is not observable in the
present picture) whereas the wild-type product remains uncleaved
(111 bp). Upper panel: Piericidin sensitivity of Complex I in the dif-
ferent strains. Membranes of mutants and parental R. capsulatus
were characterized by oxygraphy. The NADH dependent respiration
was measured in the absence or presence of 12 nM piericidin. This
piericidin concentration was chosen as it resulted in a total inhibi-
tion of respiration for membranes of B10, W1 and Myx1 (50% in-
hibitory concentration (IC50) = 0.2 nM) but induced only about 60%
inhibition of the respiration of PiRC mutant (IC50 = 6 nM).
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zymes. The 2.45 Aî resolution structure of QA and QB quinone
binding sites of the reaction center of photosynthetic bacteria
suggests that quinone binding sites are located at the interface
between the membranous domain and the cytosolic domain of
quinone binding enzymes [10]. The ‘quinone ring pocket’ of
the QB site is located at the interface between the transmem-
branous L subunit and the cytosolic H subunit of the reaction
center whereas the isoprenyl motif is diving into the membra-
nous part of subunit L [10]. In this regard, it is interesting to
note that the reaction center inhibitor stigmatellin essentially
occupies the ‘quinone ring pocket’. It is also worth noting that
mutations associated with stigmatellin resistance precisely tar-
get essential residues of this pocket [8,10]. On the other hand,
one molecule of lauryl dimethyl aminoxide (LDAO) binds to
the QB ‘isoprenyl subsite’ of the reaction center crystallized in
the absence of added quinone [10]. In the case of bc1 complex,
crystallographic data also revealed that the inhibitors myxo-
thiazol and antimycin, known to target, respectively, the QP
and QN ubiquinone binding sites of the bc1 complex, bind
close to the interface between the membrane and the periph-
eral parts of the enzyme [11]. Here again, the e⁄ciency and
reliability of genetic studies of inhibitor resistant mutants for
the mapping of quinone/inhibitor binding sites was validated
by crystallographic data [9,11]. By analogy with the structure
of the QB site of the reaction center, it can be proposed that
each quinone binding site of Complex I would be constituted
of a polar ‘quinone ring’ subsite and a membranous ‘isoprenyl
tail’ subsite. Along this line, the di¡erent inhibitors of Com-
plex I should be classi¢ed as inhibitors targeting preferentially
the polar subsite(s) and inhibitors targeting preferentially the
hydrophobic part of the quinone sites. This rationale would
explain the great structural diversity and the observed partial
competition between inhibitors of Complex I. The Complex I
situation would parallel the observations made on the QP site
inhibitors stigmatellin and methoxyacrylates in the case of the
bc1 complex. The di¡erent behavior of stigmatellin and me-
thoxyacrylate derivatives appears to result from di¡erential
interaction with, respectively, the ‘quinone ring’- and ‘isopren-
yl tail’-binding regions of the QP site [27].
Among the numerous inhibitors of Complex I, piericidin is
one of the most potent. It displays a very high a⁄nity for
mitochondrial and bacterial Complexes I and is considered
to be a direct antagonist of quinones [5,28]. As noted previ-
ously [29], the overall chemical structure of piericidin is clearly
related to that of ubiquinones: it presents a polar heterocycle
similar to the ubiquinone ring with a branched aliphatic chain
reminiscent of the isoprenyl motif of ubiquinones (Fig. 3).
Semiquinones have long been observed in association with
Complex I and are postulated to take part in the energetic
coupling between proton and electron £uxes [3,30^32]. In this
regard, it is interesting to note that, like stigmatellin [10],
piericidin can be viewed as an analogue of semi-ubiquinone.
Similarly to stigmatellin in the case of the reaction center and
the bc1 complex, piericidin would thus essentially target the
‘quinone ring’-binding subsite(s) of Complex I. Accordingly,
the identi¢cation of the NUODV407M mutation character-
ized here constitutes the ¢rst direct evidence for the participa-
tion of the C-terminal part of the NUOD subunit in the
structure of a ‘quinone ring’ subsite of Complex I. As our
mutants are resistant both to rotenone and piericidin, this
subsite would be shared by rotenone, piericidin and quinone.
The carboxy-terminus of NUOD is remarkably conserved,
both in similarity and length, between higher eukaryotes
and bacteria (Fig. 1). Interestingly, Complex I of E. coli is
relatively insensitive to piericidin and rotenone [28] and the
enzymes of both E. coli and T. thermophilus are reported to
preferentially use menaquinone instead of ubiquinone as sub-
strate [33,34]. This may be tentatively associated with the fact
that, although Val407 is conserved in E. coli NUOCD and T.
thermophilus NQO4, the carboxy-termini of these proteins are
only weakly homologous with those of mitochondria, R. cap-
sulatus and P. denitri¢cans (Fig. 1).
The dimethoxy derivatized ring A of rotenone appears
structurally related to the quinone head of ubiquinone (Fig.
3). Structure-function relationship studies of rotenone ana-
logues suggest that the A-B cycles of rotenone mimic the
quinone ring of ubiquinone [35]. Along this line, the C-D-E
cycles must functionally correspond to the hydrophobic ‘iso-
prenyl tail’ of ubiquinone. Both arylazidomorphigenin and
dihydrorotenone photochemically reactive groups are located
at the level of the E cycle and must therefore react essentially
with the peptides lining the ‘isoprenyl-tail’ binding subsite.
Thus, photolabelling with these rotenones actually points to
the ND1 subunit as a candidate subunit for the ‘isoprenyl-tail’
binding subsite [6,7]. It is well known that an isolated periph-
eral fragment of Complex I devoid of all the ND subunits is
still able to catalyze NADH-quinone oxidoreduction, espe-
cially with short-tailed quinones [24,26]. This last observation
is consistent with the idea that ubiquinone binding sites are
actually located at the interface between membranous and
peripheral domains of Complex I. The overall organization
of the piericidin/quinone binding site can therefore be pro-
posed to be constituted of a hydrophobic pocket borne by
the ND1/NUOH subunit and a polar head borne by the 49-
kDa/NUOD subunit as illustrated in Fig. 3.
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